Table_1_Impact of Eating Speed on Muscle Mass in Older Patients With Type 2 Diabetes: A Prospective Study of KAMOGAWA–DM Cohort.docx by Genki Kobayashi (1817590)

“…Muscle mass was assessed using a multifrequency impedance body composition analyzer, and skeletal muscle mass (SMI) decrease (kg/m²/year) was defined as [baseline SMI (kg/m²)–follow–up SMI (kg/m²)] ÷ follow–up duration (year). …”

The efficacy of colchicine compared to placebo for preventing ischemic stroke among individuals with established atherosclerotic cardiovascular diseases: a systematic review and me... by Shulai Zhu (20443603)

“…PubMed, Scopus, Web of Science, and the Cochrane Library were systematically searched from the inception to August 5, 2024. A random-effects (DerSimonian–Laird) model was used to conduct this meta-analysis. …”

Data_Sheet_1_Bacteroides fragilis Prevents Clostridium difficile Infection in a Mouse Model by Restoring Gut Barrier and Microbiome Regulation.pdf by Huimin Deng (1844299)

“…Notably, the abundance of Bacteroides fragilis was reported to be significantly decreased in CDAD patients. This study aimed to clarify the prophylactic effects of B. fragilis strain ZY-312 in a mouse model of C. difficile infection (CDI). …”

Data_Sheet_1_Bacteroides fragilis Prevents Clostridium difficile Infection in a Mouse Model by Restoring Gut Barrier and Microbiome Regulation.pdf by Huimin Deng (1844299)

“…Notably, the abundance of Bacteroides fragilis was reported to be significantly decreased in CDAD patients. This study aimed to clarify the prophylactic effects of B. fragilis strain ZY-312 in a mouse model of C. difficile infection (CDI). …”

DataSheet1_Efficacy and safety of danshen class injections in the treatment of coronary heart disease: a network meta-analysis.docx by Shuang Dai (1413496)

“…NMA was conducted using RevMan 5.3 and Stata 16.0 software.</p>Results<p>A total of 106 studies including 14,979 patients, involving 10,931 patients, with 5,640 in the experimental group and 5,291 in the control group. …”

NS restores macrophage autophagy and alleviates the progression of atherosclerosis by inhibiting the PI3K/Akt/mTOR pathway. by Yihua Wang (491766)

Supplementary Material for: Increased Spleen Volume in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab in Comparison to Lenvatinib: A Retrospective Ana... by Hatanaka T. (11765621)

“…The mALBI grade was classified as 1, 2a, 2b, and 3 in 10 (38.5%), 6 (23.1%), 10 (38.5%), and zero (0.0%) patients, respectively, in the Atez/Bev group and 21 (45.7%), 9 (19.6%), 15 (32.6%), and 1 (2.2%) patient in the LEN group (<i>p</i> = 0.9). …”

Model vs. WKY group KEGG pathways (Top 15). by Xiao Zhang (152326)

“…</p><p>Results</p><p>From Day 1–5, compared with the WKY group, both the Model and SHR groups exhibited shortened incubation periods and slower average swimming speeds (<i><i>P</i></i> < 0.01); On day 6, compared with the WKY group, the Model group showed a significant decrease in the number of platform crossings (<i><i>P</i></i> < 0.05), time spent in the target quadrant (<i><i>P</i></i> < 0.05), and total distance traveled in the target quadrant (<i><i>P</i></i> < 0.05). …”

Behavioral data. by Xiao Zhang (152326)

“…</p><p>Results</p><p>From Day 1–5, compared with the WKY group, both the Model and SHR groups exhibited shortened incubation periods and slower average swimming speeds (<i><i>P</i></i> < 0.01); On day 6, compared with the WKY group, the Model group showed a significant decrease in the number of platform crossings (<i><i>P</i></i> < 0.05), time spent in the target quadrant (<i><i>P</i></i> < 0.05), and total distance traveled in the target quadrant (<i><i>P</i></i> < 0.05). …”

OPLS-DA model parameter. by Xiao Zhang (152326)

“…</p><p>Results</p><p>From Day 1–5, compared with the WKY group, both the Model and SHR groups exhibited shortened incubation periods and slower average swimming speeds (<i><i>P</i></i> < 0.01); On day 6, compared with the WKY group, the Model group showed a significant decrease in the number of platform crossings (<i><i>P</i></i> < 0.05), time spent in the target quadrant (<i><i>P</i></i> < 0.05), and total distance traveled in the target quadrant (<i><i>P</i></i> < 0.05). …”

Model vs. SHR group KEGG pathways (Top 15). by Xiao Zhang (152326)

“…</p><p>Results</p><p>From Day 1–5, compared with the WKY group, both the Model and SHR groups exhibited shortened incubation periods and slower average swimming speeds (<i><i>P</i></i> < 0.01); On day 6, compared with the WKY group, the Model group showed a significant decrease in the number of platform crossings (<i><i>P</i></i> < 0.05), time spent in the target quadrant (<i><i>P</i></i> < 0.05), and total distance traveled in the target quadrant (<i><i>P</i></i> < 0.05). …”

The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis by Ingrid Lindquist (262581)

“…Total periprocedural bleeding was decreased in patients who received TPO-RAs (11.6% vs 15.6%, RR 0.64, 95% CI 0.5–0.9 <i>p</i> = .01. …”

Table 4_Association between cardiovascular health and markers of liver function: a cross-sectional study from NHANES 2005–2018.docx by Huang Yu (5882174)

“…</p>Results<p>Linear regression analysis showed that each 1-point increase in CVH score was significantly associated with decreased levels of liver enzymes [ALT: −0.200 U/L (95% CI: −0.223, −0.176), AST: −0.043 U/L (−0.062, −0.024), GGT: −0.453 U/L (−0.509, −0.397), ALP: −0.310 U/L (−0.340, −0.281)] and increased levels of albumin [0.040 g/dL (0.036, 0.045)] and AST/ALT ratio [0.0056 (0.0051, 0.0061)]. …”

Table 2_Association between cardiovascular health and markers of liver function: a cross-sectional study from NHANES 2005–2018.docx by Huang Yu (5882174)

“…</p>Results<p>Linear regression analysis showed that each 1-point increase in CVH score was significantly associated with decreased levels of liver enzymes [ALT: −0.200 U/L (95% CI: −0.223, −0.176), AST: −0.043 U/L (−0.062, −0.024), GGT: −0.453 U/L (−0.509, −0.397), ALP: −0.310 U/L (−0.340, −0.281)] and increased levels of albumin [0.040 g/dL (0.036, 0.045)] and AST/ALT ratio [0.0056 (0.0051, 0.0061)]. …”

Table 3_Association between cardiovascular health and markers of liver function: a cross-sectional study from NHANES 2005–2018.docx by Huang Yu (5882174)

“…</p>Results<p>Linear regression analysis showed that each 1-point increase in CVH score was significantly associated with decreased levels of liver enzymes [ALT: −0.200 U/L (95% CI: −0.223, −0.176), AST: −0.043 U/L (−0.062, −0.024), GGT: −0.453 U/L (−0.509, −0.397), ALP: −0.310 U/L (−0.340, −0.281)] and increased levels of albumin [0.040 g/dL (0.036, 0.045)] and AST/ALT ratio [0.0056 (0.0051, 0.0061)]. …”

Table 1_Association between cardiovascular health and markers of liver function: a cross-sectional study from NHANES 2005–2018.docx by Huang Yu (5882174)

“…</p>Results<p>Linear regression analysis showed that each 1-point increase in CVH score was significantly associated with decreased levels of liver enzymes [ALT: −0.200 U/L (95% CI: −0.223, −0.176), AST: −0.043 U/L (−0.062, −0.024), GGT: −0.453 U/L (−0.509, −0.397), ALP: −0.310 U/L (−0.340, −0.281)] and increased levels of albumin [0.040 g/dL (0.036, 0.045)] and AST/ALT ratio [0.0056 (0.0051, 0.0061)]. …”

Table_1_Differences in Decision-Making Behavior Between Elite and Amateur Team-Handball Players in a Near-Game Test Situation.DOCX by Matthias Hinz (12398539)

“…To address this point, our study compared elite and amateur players’ decision-making behavior in a near-game test environment including sport-specific sensorimotor responses. …”

Diagnostic criteria for Alcoholic cardiomyopathy. by Fei Yan (128878)

“…</p><p><b>Results:</b> Globally, ACM burden showed significant declines from 1990 to 2021, with age-standardized rates decreasing by 22.5-37.1% across prevalence, mortality and disability measures. …”

Multiple comparisons after ANOVA(CR10). by Xinyu Dai (5100731)

“…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …”

Homogeneity test of CR10. by Xinyu Dai (5100731)

“…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …”